Alkermes Q3 2023 revenue $380.9M, GAAP net income $47.8M; reiterates FY guidance; oncology split in Nov

Alkermes plc.

2023-Q3 EPS reported $1.42 revenue$1,285,930,000

Total Q3 revenues $380.9M vs $252.4M YoY; proprietary product sales up 16% to $231.8M.
GAAP net income $47.8M ($0.28 diluted EPS) vs GAAP net loss of $64.0M YoY; non-GAAP net income $109.5M ($0.64 diluted EPS).
LYBALVI net sales $50.7M (+87% YoY); VIVITROL $99.3M (+3%); ARISTADA $81.8M (+8%).
Cash & investments $995.6M; debt $291.4M; reiterates FY2023 guidance.
Expects oncology spin-off (Mural) Nov 2023 with $275M; settled VIVITROL patent suit with Teva (generic Jan 2027).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alkermes plc. updated its three and nine months ended September 30, 2023 guidance (reaffirmed).

Period: three and nine months ended September 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On October 25, 2023, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0000950170-23-054999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.